The prestigious Advanced Therapies Awards, held on January 22 during Advanced Therapies Week in Dallas, USA, brought together industry leaders in the fields of cell and gene therapy, regenerative medicine and biopharmaceuticals.
At the event, the IMPACT Center and the startup EVast Bio, focused on the development of extracellular vesicles, were finalists in the Technology Disruptor of the Year Award. And although the winner in this category was the microbubble-based cell separation technology development company, Akadeum Life Sciences, for the Director of the national center of excellence, Maroun Khoury, the nomination was a recognition of the work done.
We were the only research center nominated among consolidated biotechnology companies. This is a recognition of our ability to generate technological advances with transformative potential and also a reinforcement of our credibility with the scientific, medical and business community. This nomination also allowed us to be present at the Advanced Therapies Week, which is probably the largest platform to connect with industry leaders, emerging companies and potential investors. Therefore, the nomination is for us an award in itself,” explained IMPACT’s Director.
The Advanced Therapies Week is considered the industry event for advanced therapies. This version counted with the participation of companies, scientists, academics, investors and specialists from different branches of medicine and biology, where topics on the latest knowledge and trends in the area were addressed, bringing together more than 2,200 people and more than 250 conferences, which analyzed different perspectives on the current outlook, industry challenges and untapped opportunities. Through real-world examples and case studies, they showed the strategic advantages of understanding where the industry is headed and where your investments can have the greatest impact on different aspects of healthcare.